Search PubMed⌕ Search

Biomedical subjects

Anders Himmelmann

Publications and source records attributed to Anders Himmelmann.

15 recordsLinked to original sources
PubMed2004

Prediction of future hypertension by casual blood pressure or invasive hemodynamics? A 30-year follow-up study.

Blood pressure elevation in young age is associated with a risk of developing hypertension. However, not all subjects will progress to clinical hypertensives in need of pharmacological therapy. In younger subjects, there is essential to find clinical or experimental characteristics to predict the future risk of hypertension. In the present study, the long-term relationship between casual blood pressure measurement and future hypertension has been examined. The initial study group consisted of 20-year-old men (n = 44) with mild blood pressure elevation and a normotensive male control group (n = 29). After 30 years, we re-examined 32 (72%) of the subjects with previous mild blood pressure elevation and 21 (73%) of the controls. We further analyzed possible associations between blood pressure level at follow-up and anthropometric data, and invasively measured hemodynamic variables at baseline. After 30 years, 38% in the group with blood pressure elevation at baseline had developed hypertension, as compared to 10% in the control group. There was a significant positive relationship between baseline systolic blood pressure (r = 0.56; p < 0.001) and diastolic blood pressure (r = 0.36; p < 0.01) and systolic blood pressure 30 years later. In further regression analyses, there were no associations between cardiac output, vascular resistance or anthropometric data at baseline and blood pressure at follow-up. In conclusion, casual blood pressure measurements predict the risk of future hypertension, whereas invasive hemodynamic and anthropometric measurements do not in young men with mild blood pressure elevation.

Adult↗
PubMed2003

The impact of smoking on inhaled insulin.

OBJECTIVE: This study, one of the first to address issues of pulmonary insulin delivery in smokers, compared pharmacokinetics of inhaled insulin delivered via the AERx insulin Diabetes Management System (iDMS) in nondiabetic cigarette smokers and nonsmokers. RESEARCH DESIGN AND METHODS: In this randomized two-period crossover efficacy and safety trial in 27 nondiabetic smokers and 16 nonsmokers (18 men/25 women, mean age 28 years, mean BMI 23.0 kg/m(2)), subjects received single doses of inhaled insulin (33.8 IU) following overnight fasting on consecutive dosing days. On one dosing day, smokers smoked three cigarettes immediately before insulin administration ("acute smoking"); on the other dosing day, smokers had not smoked since midnight ("nonacute smoking"). After inhalation, 6-h serum insulin and serum glucose profiles were determined. RESULTS: Pharmacokinetic results for evaluable subjects were derived from serum insulin profiles. The amount of insulin absorbed during the first 6 h after dosing (area under the exogenous serum insulin curve from 0 to 6 h [AUC((0-6 h))]) was significantly greater in smokers (63.2 vs. 40.0 mU l(-1) x h(-1), P = 0.0017); peak concentration was both higher and earlier in the smokers (maximal serum concentration of insulin [C(max)] 42.0 vs. 13.9 mU/l, P < 0.0001; time to maximal serum concentration of insulin [t(max)] 31.5 vs. 53.9 min, P = 0.0003). The estimated intrasubject variability of AUC((0-6 h)) was 13.7 and 16.5% for nonsmokers and smokers, respectively. No safety issues arose. CONCLUSIONS: Absorption of inhaled insulin via the AERx iDMS was significantly greater in smokers, with a higher AUC((0-6 h)) and C(max) and a shorter t(max). Intrasubject variability of AUC((0-6 h)) was low and similar in nonsmokers and smokers. These data prompt more extensive investigation of inhaled insulin in diabetic smokers.

Administration, Inhalation↗